Harmony Biosciences (HRMY)

Its lead commercial product is WAKIX, the U.S. brand name for pitolisant. WAKIX is used in narcolepsy and works differently from many traditional wake-promoting agents because it acts on histamine H3 receptors, increasing histamine signalling in the brain. This mechanism is central to Harmony’s strategy, as the company continues to study pitolisant across additional patient groups and neurological conditions where excessive daytime sleepiness or related symptoms may be clinically important.

Harmony’s pipeline broadens the company beyond its initial narcolepsy franchise. Its candidates include HBS-102, an MCHR1 antagonist; BP1.15205, an orexin-2 receptor agonist; ZYN002, a pharmaceutically manufactured cannabidiol gel; and epilepsy-focused assets such as EPX-100 and EPX-200. These programmes give Harmony exposure to several rare or underserved neurological markets while keeping the company’s research focus relatively specialised.

As a listed biotechnology stock, HRMY is closely tied to WAKIX sales performance, label expansion opportunities, clinical trial execution, and regulatory progress. Investors typically view Harmony as a rare-disease neurology company with an established commercial base and a pipeline designed to extend its presence in central nervous system disorders.